NHMRC Glaucoma Guidelines - ANZGIG
NHMRC Glaucoma Guidelines - ANZGIG
NHMRC Glaucoma Guidelines - ANZGIG
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>NHMRC</strong> GUIDELINES FOR THE SCREENING, PROGNOSIS, DIAGNOSIS, MANAGEMENT AND PREVENTION OF GLAUCOMA<br />
Chapter 6 – Identifying those at risk of developing glaucoma<br />
Risk factors for specific glaucoma types and stages<br />
Angle closure<br />
The American Academy of Ophthalmology [AAO] (2005a) states that risk factors for developing<br />
angle closure are hypermetropia, family history of angle closure, advancing age, female gender,<br />
Asian or Inuit descent and shallow anterior chamber for PACG. However, there is limited<br />
quantification of the risk. Medical interactions/effects are also a proposed risk, however even<br />
less is known about them. Schmier, Halpern and Jones (2007) state that the higher prevalence of<br />
primary angle closure (PAC) and PACG in Asian and certain indigenous ethnic groups (e.g. Inuit)<br />
suggests that ethnicity is a risk for that glaucoma type.<br />
These guidelines report medications and conditions associated with the development of angle<br />
closure states in Chapter 9.<br />
Evidence Statement<br />
• Expert/consensus opinion suggests that hypermetropia, family history of angle closure, advancing age,<br />
female gender, Asian descent and shallow anterior chamber are risk factors for the development of angle<br />
closure, and angle closure glaucoma.<br />
Secondary glaucoma<br />
There is no evidence from the secondary literature regarding the risk factors for, or progression<br />
of secondary glaucoma.<br />
Progression of established glaucoma<br />
Risk factors for developing glaucoma are not necessarily the same as the risk factors for progression of<br />
diagnosed glaucoma. However, the importance of IOP in early stage glaucoma has been underlined<br />
by the results of the Ocular Hypertension Treatment Study (Budenz et al 2006), wherein univariate<br />
and multivariate analyses found that every 1 mmHg increase in mean IOP level was associated with<br />
a 10% increased risk of progression from OH to glaucoma. A meta-analysis of five relevant and<br />
adequately powered studies (Maier, Funk, Schwarzer et al 2005) also concluded that using topical<br />
pressure lowering medications for primary prevention of glaucomatous VF defects in patients with<br />
OH appears to be effective. The Ocular Hypertension Treatment Study (Budenz et al 2006) also<br />
reported that subjects with optic disc rim haemorrhage were four to six times as likely to progress<br />
to glaucoma as those without optic disc rim haemorrhage. The Early Manifest <strong>Glaucoma</strong> Treatment<br />
Trial (Leske et al 2004) concurred, reporting that patients with optic disc rim haemorrhage were<br />
more likely to progress to glaucoma, with a strong relationship established between frequency of<br />
optic disc rim haemorrhage and risk of progression.<br />
Evidence Statement<br />
Evidence indicates that factors associated with greater risk of glaucoma progression include elevated/<br />
fluctuating intraocular pressure, optic disc haemorrhage, increased severity of glaucomatous disc damage<br />
and very low blood pressure. These patients require greater reduction in intraocular pressure.<br />
National Health and Medical Research Council 59